Top Sanofi vaccine execs, Bristol Myers vet chart new path for IGM’s antibodies in infectious diseases, autoimmunity

When IGM Biosciences made its public debut two years ago, the S-1 pitch was heavily centered on how its engineered IgM antibodies could make potent cancer treatments. But it also buried a reference, deep inside a section about the platform’s potential, about how these antibodies may be applied in a...

Click to view original post